Mirabegron versus placebo and other therapeutic modalities in the treatment of patients with Overactive Bladder Syndrome : A Systematic Review
| dc.contributor.author | Dey, Anirban | |
| dc.contributor.author | Georgiadis, Georgios | |
| dc.contributor.author | Umezurike, Justin | |
| dc.contributor.author | Yuan, Yuhong | |
| dc.contributor.author | Farag, Fawzy | |
| dc.contributor.author | N'Dow, James | |
| dc.contributor.author | Omar, Muhammad Imran | |
| dc.contributor.author | Mamoulakis, Charalampos | |
| dc.contributor.institution | University of Aberdeen.Other Applied Health Sciences | en |
| dc.contributor.institution | University of Aberdeen.Academic Urology Unit | en |
| dc.contributor.institution | University of Aberdeen.Institute of Applied Health Sciences | en |
| dc.date.accessioned | 2025-09-16T23:09:28Z | |
| dc.date.issued | 2024-09-28 | |
| dc.description.status | Peer reviewed | en |
| dc.format.extent | 14 | |
| dc.format.extent | 533887 | |
| dc.identifier | 293490551 | |
| dc.identifier | e10b2d27-cb22-4303-9cc6-8366b90a633d | |
| dc.identifier | 85205264555 | |
| dc.identifier | 39343691 | |
| dc.identifier.citation | Dey, A, Georgiadis, G, Umezurike, J, Yuan, Y, Farag, F, N'Dow, J, Omar, M I & Mamoulakis, C 2024, 'Mirabegron versus placebo and other therapeutic modalities in the treatment of patients with Overactive Bladder Syndrome : A Systematic Review', European Urology Focus. https://doi.org/10.1016/j.euf.2024.09.012 | en |
| dc.identifier.doi | 10.1016/j.euf.2024.09.012 | |
| dc.identifier.issn | 2405-4569 | |
| dc.identifier.other | ORCID: /0000-0001-5340-0081/work/168605986 | |
| dc.identifier.other | ORCID: /0000-0002-1597-3126/work/168607671 | |
| dc.identifier.uri | https://hdl.handle.net/2164/26028 | |
| dc.language.iso | eng | |
| dc.relation.ispartof | European Urology Focus | en |
| dc.subject | Mirabegron | en |
| dc.subject | Overactive bladder syndrome | en |
| dc.subject | Randomised controlled trials | en |
| dc.subject | Urgency urinary incontinence | en |
| dc.subject | Nocturia | en |
| dc.subject | Imidafenacin | en |
| dc.subject | Tolterodine | en |
| dc.subject | Solifenacin | en |
| dc.subject | Oxybutynin | en |
| dc.subject | Preferred Reporting Items for Systematic Reviews and Metaanalyses | en |
| dc.subject | R Medicine (General) | en |
| dc.subject | Supplementary Data | en |
| dc.subject | https://ars.els-cdn.com/content/image/1-s2.0-S2405456924001810-mmc1.docx | en |
| dc.subject.lcc | R1 | en |
| dc.title | Mirabegron versus placebo and other therapeutic modalities in the treatment of patients with Overactive Bladder Syndrome : A Systematic Review | en |
| dc.type | Journal article | en |
Files
Original bundle
1 - 1 of 1
- Name:
- Dey_etal_EUF_Mirabegron_versus_placebo_AAM.pdf
- Size:
- 521.37 KB
- Format:
- Adobe Portable Document Format
